Patented Curcumin targets depression & anxiety in EU Market

An ingredient formed through a turmeric extract and proven to help mitigate symptoms of depression and anxiety has been brought to the European market by Arjuna Natural Extracts.

Results from a 2014 study involving 56 individuals with a major depressive disorder showed that the supplementation of the BCM-95 Curcumin succeeded in reducing the systems of depression when taken over a period of eight weeks.

According to an Arjuna Natural Extracts spokesman, the treatment was most effective in the group of individuals with common depression –with no significant differences adverse effects between BCM-95 and the placebo.

“It appears to elevate neurotransmitters such as serotonin, while lowering stress hormones, such as cortisol, and is a potent antioxidant and anti-flammatory. Curcumin also provides protection to the brain,” Arjuna said.

Health surveys indicate that major depression is experienced by 10-15 per cent of people in their lifetime, with a success rate of current treatment currently sitting at 20-40 per cent. Side effects from long-term treatments include anxiety, thoughts of suicide, insomnia, weight gain and sexual dysfunction.  

Manufactured by combining Curcumin and essential oil of turmeric, the BCM-95 curcumin has been extensively researched by universities throughout the US, Australia, Japan and India in multiple clinical studies and attained 12 international patents.

Curcumin works simultaneously on multiple pathways associated with depression. It is considered as the most promising therapeutic targets to treat depressive behaviour.

Arjuna continues to engage in research and development, with continuing scientific validation of its novel product line through advanced clinical studies.